nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenylpropanolamine—Levonordefrin—Salbutamol—chronic obstructive pulmonary disease	0.219	1	CrCrCtD
Phenylpropanolamine—ADRB2—chronic obstructive pulmonary disease	0.186	0.547	CbGaD
Phenylpropanolamine—CYP1A2—chronic obstructive pulmonary disease	0.154	0.453	CbGaD
Phenylpropanolamine—ADRB2—Salbutamol—chronic obstructive pulmonary disease	0.0709	0.193	CbGbCtD
Phenylpropanolamine—ADRB1—Salbutamol—chronic obstructive pulmonary disease	0.0699	0.19	CbGbCtD
Phenylpropanolamine—ADRB2—Arformoterol—chronic obstructive pulmonary disease	0.0538	0.146	CbGbCtD
Phenylpropanolamine—ADRB2—Formoterol—chronic obstructive pulmonary disease	0.0538	0.146	CbGbCtD
Phenylpropanolamine—ADRB1—Formoterol—chronic obstructive pulmonary disease	0.0529	0.144	CbGbCtD
Phenylpropanolamine—ADRB1—Arformoterol—chronic obstructive pulmonary disease	0.0529	0.144	CbGbCtD
Phenylpropanolamine—CYP1A2—Aminophylline—chronic obstructive pulmonary disease	0.0139	0.0378	CbGbCtD
Phenylpropanolamine—Respiratory depression—Aminophylline—chronic obstructive pulmonary disease	0.0013	0.0286	CcSEcCtD
Phenylpropanolamine—Pulmonary function test decreased—Aminophylline—chronic obstructive pulmonary disease	0.0013	0.0286	CcSEcCtD
Phenylpropanolamine—Liver injury—Montelukast—chronic obstructive pulmonary disease	0.000867	0.0191	CcSEcCtD
Phenylpropanolamine—Blood pressure increased—Formoterol—chronic obstructive pulmonary disease	0.000745	0.0164	CcSEcCtD
Phenylpropanolamine—Blood pressure increased—Arformoterol—chronic obstructive pulmonary disease	0.000745	0.0164	CcSEcCtD
Phenylpropanolamine—Hepatocellular injury—Montelukast—chronic obstructive pulmonary disease	0.00073	0.0161	CcSEcCtD
Phenylpropanolamine—Blood pressure increased—Salbutamol—chronic obstructive pulmonary disease	0.000704	0.0155	CcSEcCtD
Phenylpropanolamine—Irritability—Aminophylline—chronic obstructive pulmonary disease	0.000678	0.0149	CcSEcCtD
Phenylpropanolamine—Urinary retention—Aminophylline—chronic obstructive pulmonary disease	0.000676	0.0149	CcSEcCtD
Phenylpropanolamine—Urinary retention—Tiotropium—chronic obstructive pulmonary disease	0.000637	0.014	CcSEcCtD
Phenylpropanolamine—Tension—Roflumilast—chronic obstructive pulmonary disease	0.00063	0.0139	CcSEcCtD
Phenylpropanolamine—Nervousness—Roflumilast—chronic obstructive pulmonary disease	0.000623	0.0137	CcSEcCtD
Phenylpropanolamine—Euphoric mood—Salbutamol—chronic obstructive pulmonary disease	0.000604	0.0133	CcSEcCtD
Phenylpropanolamine—Tremor—Roflumilast—chronic obstructive pulmonary disease	0.000601	0.0132	CcSEcCtD
Phenylpropanolamine—Anxiety—Roflumilast—chronic obstructive pulmonary disease	0.000544	0.012	CcSEcCtD
Phenylpropanolamine—Irritability—Montelukast—chronic obstructive pulmonary disease	0.000506	0.0111	CcSEcCtD
Phenylpropanolamine—Irritability—Salbutamol—chronic obstructive pulmonary disease	0.000487	0.0107	CcSEcCtD
Phenylpropanolamine—Ataxia—Salbutamol—chronic obstructive pulmonary disease	0.00048	0.0106	CcSEcCtD
Phenylpropanolamine—Insomnia—Roflumilast—chronic obstructive pulmonary disease	0.000474	0.0104	CcSEcCtD
Phenylpropanolamine—Flushing—Aminophylline—chronic obstructive pulmonary disease	0.000456	0.01	CcSEcCtD
Phenylpropanolamine—Constipation—Roflumilast—chronic obstructive pulmonary disease	0.000448	0.00986	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Aminophylline—chronic obstructive pulmonary disease	0.000439	0.00967	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Roflumilast—chronic obstructive pulmonary disease	0.000432	0.0095	CcSEcCtD
Phenylpropanolamine—Tension—Aminophylline—chronic obstructive pulmonary disease	0.00042	0.00924	CcSEcCtD
Phenylpropanolamine—Nervousness—Aminophylline—chronic obstructive pulmonary disease	0.000416	0.00915	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Tiotropium—chronic obstructive pulmonary disease	0.000414	0.00912	CcSEcCtD
Phenylpropanolamine—Drowsiness—Montelukast—chronic obstructive pulmonary disease	0.000408	0.00899	CcSEcCtD
Phenylpropanolamine—Tremor—Aminophylline—chronic obstructive pulmonary disease	0.000401	0.00883	CcSEcCtD
Phenylpropanolamine—Drowsiness—Salbutamol—chronic obstructive pulmonary disease	0.000394	0.00866	CcSEcCtD
Phenylpropanolamine—Agitation—Aminophylline—chronic obstructive pulmonary disease	0.000393	0.00866	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Roflumilast—chronic obstructive pulmonary disease	0.000386	0.00849	CcSEcCtD
Phenylpropanolamine—Vision blurred—Tiotropium—chronic obstructive pulmonary disease	0.00038	0.00837	CcSEcCtD
Phenylpropanolamine—Hallucination—Montelukast—chronic obstructive pulmonary disease	0.000365	0.00803	CcSEcCtD
Phenylpropanolamine—Anxiety—Aminophylline—chronic obstructive pulmonary disease	0.000363	0.00799	CcSEcCtD
Phenylpropanolamine—Euphoric mood—Prednisolone—chronic obstructive pulmonary disease	0.000347	0.00763	CcSEcCtD
Phenylpropanolamine—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.000346	0.00762	CcSEcCtD
Phenylpropanolamine—Tachycardia—Aminophylline—chronic obstructive pulmonary disease	0.000341	0.0075	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Arformoterol—chronic obstructive pulmonary disease	0.000334	0.00736	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Formoterol—chronic obstructive pulmonary disease	0.000334	0.00736	CcSEcCtD
Phenylpropanolamine—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.000333	0.00733	CcSEcCtD
Phenylpropanolamine—Rash—Roflumilast—chronic obstructive pulmonary disease	0.00033	0.00727	CcSEcCtD
Phenylpropanolamine—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.00033	0.00726	CcSEcCtD
Phenylpropanolamine—Flushing—Salbutamol—chronic obstructive pulmonary disease	0.000328	0.00722	CcSEcCtD
Phenylpropanolamine—Hypotension—Aminophylline—chronic obstructive pulmonary disease	0.000326	0.00718	CcSEcCtD
Phenylpropanolamine—Tachycardia—Tiotropium—chronic obstructive pulmonary disease	0.000321	0.00708	CcSEcCtD
Phenylpropanolamine—Tension—Formoterol—chronic obstructive pulmonary disease	0.00032	0.00704	CcSEcCtD
Phenylpropanolamine—Tension—Arformoterol—chronic obstructive pulmonary disease	0.00032	0.00704	CcSEcCtD
Phenylpropanolamine—Nervousness—Arformoterol—chronic obstructive pulmonary disease	0.000316	0.00696	CcSEcCtD
Phenylpropanolamine—Nervousness—Formoterol—chronic obstructive pulmonary disease	0.000316	0.00696	CcSEcCtD
Phenylpropanolamine—Insomnia—Aminophylline—chronic obstructive pulmonary disease	0.000316	0.00695	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Salbutamol—chronic obstructive pulmonary disease	0.000316	0.00695	CcSEcCtD
Phenylpropanolamine—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.000311	0.00685	CcSEcCtD
Phenylpropanolamine—Tremor—Arformoterol—chronic obstructive pulmonary disease	0.000305	0.00672	CcSEcCtD
Phenylpropanolamine—Tremor—Formoterol—chronic obstructive pulmonary disease	0.000305	0.00672	CcSEcCtD
Phenylpropanolamine—Tension—Salbutamol—chronic obstructive pulmonary disease	0.000302	0.00664	CcSEcCtD
Phenylpropanolamine—Agitation—Formoterol—chronic obstructive pulmonary disease	0.000299	0.00659	CcSEcCtD
Phenylpropanolamine—Agitation—Arformoterol—chronic obstructive pulmonary disease	0.000299	0.00659	CcSEcCtD
Phenylpropanolamine—Tremor—Montelukast—chronic obstructive pulmonary disease	0.000299	0.00658	CcSEcCtD
Phenylpropanolamine—Nervousness—Salbutamol—chronic obstructive pulmonary disease	0.000299	0.00657	CcSEcCtD
Phenylpropanolamine—Insomnia—Tiotropium—chronic obstructive pulmonary disease	0.000298	0.00656	CcSEcCtD
Phenylpropanolamine—Agitation—Montelukast—chronic obstructive pulmonary disease	0.000293	0.00645	CcSEcCtD
Phenylpropanolamine—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.000288	0.00634	CcSEcCtD
Phenylpropanolamine—Ephedrine—ADRB2—chronic obstructive pulmonary disease	0.000288	0.127	CrCbGaD
Phenylpropanolamine—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.000283	0.00622	CcSEcCtD
Phenylpropanolamine—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000282	0.0062	CcSEcCtD
Phenylpropanolamine—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000276	0.00608	CcSEcCtD
Phenylpropanolamine—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000276	0.00608	CcSEcCtD
Phenylpropanolamine—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000271	0.00596	CcSEcCtD
Phenylpropanolamine—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000261	0.00574	CcSEcCtD
Phenylpropanolamine—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000259	0.00571	CcSEcCtD
Phenylpropanolamine—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000259	0.00571	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000257	0.00566	CcSEcCtD
Phenylpropanolamine—Euphoric mood—Prednisone—chronic obstructive pulmonary disease	0.000252	0.00555	CcSEcCtD
Phenylpropanolamine—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000248	0.00547	CcSEcCtD
Phenylpropanolamine—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000248	0.00547	CcSEcCtD
Phenylpropanolamine—Pseudoephedrine—TNF—chronic obstructive pulmonary disease	0.000246	0.109	CrCbGaD
Phenylpropanolamine—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.000245	0.00539	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000243	0.00534	CcSEcCtD
Phenylpropanolamine—Insomnia—Formoterol—chronic obstructive pulmonary disease	0.00024	0.00529	CcSEcCtD
Phenylpropanolamine—Insomnia—Arformoterol—chronic obstructive pulmonary disease	0.00024	0.00529	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000237	0.00522	CcSEcCtD
Phenylpropanolamine—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000237	0.00522	CcSEcCtD
Phenylpropanolamine—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000236	0.0052	CcSEcCtD
Phenylpropanolamine—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000236	0.0052	CcSEcCtD
Phenylpropanolamine—Insomnia—Montelukast—chronic obstructive pulmonary disease	0.000236	0.00518	CcSEcCtD
Phenylpropanolamine—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000235	0.00516	CcSEcCtD
Phenylpropanolamine—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000231	0.0051	CcSEcCtD
Phenylpropanolamine—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000231	0.00508	CcSEcCtD
Phenylpropanolamine—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.000227	0.005	CcSEcCtD
Phenylpropanolamine—Constipation—Formoterol—chronic obstructive pulmonary disease	0.000227	0.005	CcSEcCtD
Phenylpropanolamine—Insomnia—Salbutamol—chronic obstructive pulmonary disease	0.000227	0.005	CcSEcCtD
Phenylpropanolamine—Tranylcypromine—CYP1A2—chronic obstructive pulmonary disease	0.000227	0.1	CrCbGaD
Phenylpropanolamine—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000224	0.00493	CcSEcCtD
Phenylpropanolamine—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000223	0.00491	CcSEcCtD
Phenylpropanolamine—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000222	0.00489	CcSEcCtD
Phenylpropanolamine—Rash—Aminophylline—chronic obstructive pulmonary disease	0.00022	0.00485	CcSEcCtD
Phenylpropanolamine—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.00022	0.00484	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000219	0.00482	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000219	0.00482	CcSEcCtD
Phenylpropanolamine—Pseudoephedrine—ADRB2—chronic obstructive pulmonary disease	0.000218	0.0965	CrCbGaD
Phenylpropanolamine—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000218	0.00479	CcSEcCtD
Phenylpropanolamine—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000215	0.00472	CcSEcCtD
Phenylpropanolamine—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000209	0.00461	CcSEcCtD
Phenylpropanolamine—Phentermine—SLC6A4—chronic obstructive pulmonary disease	0.000209	0.0925	CrCbGaD
Phenylpropanolamine—Psychotic disorder—Prednisone—chronic obstructive pulmonary disease	0.000208	0.00458	CcSEcCtD
Phenylpropanolamine—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000208	0.00457	CcSEcCtD
Phenylpropanolamine—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000207	0.00457	CcSEcCtD
Phenylpropanolamine—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.000207	0.00457	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000207	0.00455	CcSEcCtD
Phenylpropanolamine—Irritability—Prednisone—chronic obstructive pulmonary disease	0.000203	0.00447	CcSEcCtD
Phenylpropanolamine—Pseudoephedrine—SLC6A4—chronic obstructive pulmonary disease	0.000198	0.0877	CrCbGaD
Phenylpropanolamine—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000196	0.00431	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000196	0.00431	CcSEcCtD
Phenylpropanolamine—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000196	0.00431	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000192	0.00422	CcSEcCtD
Phenylpropanolamine—Phentermine—CYP1A2—chronic obstructive pulmonary disease	0.00019	0.0842	CrCbGaD
Phenylpropanolamine—Benzyl alcohol—CYP1A1—chronic obstructive pulmonary disease	0.00019	0.0842	CrCbGaD
Phenylpropanolamine—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000185	0.00407	CcSEcCtD
Phenylpropanolamine—Benzyl alcohol—CYP1A2—chronic obstructive pulmonary disease	0.000183	0.0812	CrCbGaD
Phenylpropanolamine—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.000181	0.00398	CcSEcCtD
Phenylpropanolamine—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000176	0.00387	CcSEcCtD
Phenylpropanolamine—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000176	0.00387	CcSEcCtD
Phenylpropanolamine—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000172	0.00379	CcSEcCtD
Phenylpropanolamine—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000169	0.00372	CcSEcCtD
Phenylpropanolamine—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000169	0.00372	CcSEcCtD
Phenylpropanolamine—Rash—Formoterol—chronic obstructive pulmonary disease	0.000168	0.00369	CcSEcCtD
Phenylpropanolamine—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000168	0.00369	CcSEcCtD
Phenylpropanolamine—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000167	0.00369	CcSEcCtD
Phenylpropanolamine—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000167	0.00369	CcSEcCtD
Phenylpropanolamine—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000166	0.00366	CcSEcCtD
Phenylpropanolamine—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000166	0.00365	CcSEcCtD
Phenylpropanolamine—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.000166	0.00364	CcSEcCtD
Phenylpropanolamine—Rash—Montelukast—chronic obstructive pulmonary disease	0.000164	0.00361	CcSEcCtD
Phenylpropanolamine—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000164	0.00361	CcSEcCtD
Phenylpropanolamine—Amphetamine—SLC6A4—chronic obstructive pulmonary disease	0.000161	0.0711	CrCbGaD
Phenylpropanolamine—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.00016	0.00351	CcSEcCtD
Phenylpropanolamine—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000158	0.00348	CcSEcCtD
Phenylpropanolamine—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000158	0.00348	CcSEcCtD
Phenylpropanolamine—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000158	0.00348	CcSEcCtD
Phenylpropanolamine—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000158	0.00348	CcSEcCtD
Phenylpropanolamine—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000155	0.0034	CcSEcCtD
Phenylpropanolamine—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000149	0.00328	CcSEcCtD
Phenylpropanolamine—Methamphetamine—SLC6A4—chronic obstructive pulmonary disease	0.000149	0.0659	CrCbGaD
Phenylpropanolamine—Hallucination—Prednisone—chronic obstructive pulmonary disease	0.000147	0.00322	CcSEcCtD
Phenylpropanolamine—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000141	0.00309	CcSEcCtD
Phenylpropanolamine—Flushing—Prednisone—chronic obstructive pulmonary disease	0.000137	0.00301	CcSEcCtD
Phenylpropanolamine—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	0.000132	0.0029	CcSEcCtD
Phenylpropanolamine—Insomnia—Prednisolone—chronic obstructive pulmonary disease	0.00013	0.00287	CcSEcCtD
Phenylpropanolamine—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.000121	0.00266	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000119	0.00261	CcSEcCtD
Phenylpropanolamine—Agitation—Prednisone—chronic obstructive pulmonary disease	0.000118	0.00259	CcSEcCtD
Phenylpropanolamine—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.000109	0.00239	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000106	0.00233	CcSEcCtD
Phenylpropanolamine—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.000102	0.00225	CcSEcCtD
Phenylpropanolamine—Dizziness—Prednisolone—chronic obstructive pulmonary disease	9.52e-05	0.0021	CcSEcCtD
Phenylpropanolamine—Insomnia—Prednisone—chronic obstructive pulmonary disease	9.46e-05	0.00208	CcSEcCtD
Phenylpropanolamine—Rash—Prednisolone—chronic obstructive pulmonary disease	9.08e-05	0.002	CcSEcCtD
Phenylpropanolamine—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	9.07e-05	0.002	CcSEcCtD
Phenylpropanolamine—Constipation—Prednisone—chronic obstructive pulmonary disease	8.95e-05	0.00197	CcSEcCtD
Phenylpropanolamine—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	8.62e-05	0.0019	CcSEcCtD
Phenylpropanolamine—Nausea—Prednisolone—chronic obstructive pulmonary disease	8.55e-05	0.00188	CcSEcCtD
Phenylpropanolamine—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	7.71e-05	0.0017	CcSEcCtD
Phenylpropanolamine—Dizziness—Prednisone—chronic obstructive pulmonary disease	6.92e-05	0.00152	CcSEcCtD
Phenylpropanolamine—Vomiting—Prednisone—chronic obstructive pulmonary disease	6.65e-05	0.00146	CcSEcCtD
Phenylpropanolamine—Rash—Prednisone—chronic obstructive pulmonary disease	6.6e-05	0.00145	CcSEcCtD
Phenylpropanolamine—Dermatitis—Prednisone—chronic obstructive pulmonary disease	6.59e-05	0.00145	CcSEcCtD
Phenylpropanolamine—Nausea—Prednisone—chronic obstructive pulmonary disease	6.21e-05	0.00137	CcSEcCtD
Phenylpropanolamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—EDN1—chronic obstructive pulmonary disease	2.42e-05	0.000964	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	2.42e-05	0.000963	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	2.41e-05	0.000961	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	2.4e-05	0.000955	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—TGFB2—chronic obstructive pulmonary disease	2.4e-05	0.000954	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	2.38e-05	0.00095	CbGpPWpGaD
Phenylpropanolamine—MAOA—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	2.38e-05	0.000947	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	2.38e-05	0.000947	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	2.35e-05	0.000937	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—chronic obstructive pulmonary disease	2.33e-05	0.000928	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—chronic obstructive pulmonary disease	2.33e-05	0.000928	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	2.32e-05	0.000924	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—PDE4A—chronic obstructive pulmonary disease	2.3e-05	0.000918	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	2.29e-05	0.000911	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	2.28e-05	0.000908	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	2.25e-05	0.000897	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	2.24e-05	0.000894	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	2.22e-05	0.000884	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	2.19e-05	0.000874	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	2.17e-05	0.000864	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—HDAC2—chronic obstructive pulmonary disease	2.15e-05	0.000856	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	2.14e-05	0.000854	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	2.13e-05	0.000849	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	2.12e-05	0.000846	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—chronic obstructive pulmonary disease	2.12e-05	0.000843	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	2.1e-05	0.000839	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	2.1e-05	0.000837	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	2.1e-05	0.000836	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—PDE4A—chronic obstructive pulmonary disease	2.09e-05	0.000834	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—ADRB2—chronic obstructive pulmonary disease	2.06e-05	0.000821	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Platelet activation, signaling and aggregation—SERPINE1—chronic obstructive pulmonary disease	2.04e-05	0.000813	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Platelet activation, signaling and aggregation—ALB—chronic obstructive pulmonary disease	2.04e-05	0.000811	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	2.02e-05	0.000805	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	2e-05	0.000796	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	1.99e-05	0.000794	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	1.98e-05	0.00079	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.95e-05	0.000777	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—PLAUR—chronic obstructive pulmonary disease	1.94e-05	0.000772	CbGpPWpGaD
Phenylpropanolamine—DRD1—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	1.93e-05	0.000771	CbGpPWpGaD
Phenylpropanolamine—MAOA—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	1.92e-05	0.000765	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—GC—chronic obstructive pulmonary disease	1.9e-05	0.000756	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—CXCR2—chronic obstructive pulmonary disease	1.86e-05	0.00074	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—EDN1—chronic obstructive pulmonary disease	1.84e-05	0.000734	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	1.83e-05	0.000729	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	1.82e-05	0.000723	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	1.76e-05	0.000703	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	1.76e-05	0.000699	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	1.74e-05	0.000693	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	1.73e-05	0.000691	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	1.72e-05	0.000687	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	1.7e-05	0.000678	CbGpPWpGaD
Phenylpropanolamine—DRD1—Circadian rythm related genes—TP53—chronic obstructive pulmonary disease	1.69e-05	0.000674	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—CXCR2—chronic obstructive pulmonary disease	1.69e-05	0.000672	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—G alpha (i) signalling events—CXCL8—chronic obstructive pulmonary disease	1.64e-05	0.000655	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	1.64e-05	0.000655	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	1.63e-05	0.00065	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—APIP—chronic obstructive pulmonary disease	1.63e-05	0.000648	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—HTR2A—chronic obstructive pulmonary disease	1.61e-05	0.000642	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	1.61e-05	0.000641	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	1.57e-05	0.000624	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.55e-05	0.000618	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	1.55e-05	0.000617	CbGpPWpGaD
Phenylpropanolamine—DRD1—Circadian rythm related genes—IL6—chronic obstructive pulmonary disease	1.55e-05	0.000617	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	1.54e-05	0.000614	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—GCLC—chronic obstructive pulmonary disease	1.53e-05	0.000611	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.47e-05	0.000587	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	1.47e-05	0.000587	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	1.43e-05	0.000568	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	1.41e-05	0.000561	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	1.41e-05	0.000561	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Platelet activation, signaling and aggregation—VEGFA—chronic obstructive pulmonary disease	1.4e-05	0.000559	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—CTGF—chronic obstructive pulmonary disease	1.4e-05	0.000558	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.4e-05	0.000557	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—chronic obstructive pulmonary disease	1.39e-05	0.000553	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	1.38e-05	0.000552	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—MMP1—chronic obstructive pulmonary disease	1.38e-05	0.000552	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—PLAU—chronic obstructive pulmonary disease	1.36e-05	0.000542	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	1.35e-05	0.00054	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	1.35e-05	0.000537	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	1.33e-05	0.00053	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.33e-05	0.000528	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	1.32e-05	0.000528	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—chronic obstructive pulmonary disease	1.31e-05	0.000521	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.3e-05	0.000517	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	1.3e-05	0.000516	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.29e-05	0.000514	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Platelet activation, signaling and aggregation—TGFB1—chronic obstructive pulmonary disease	1.29e-05	0.000513	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	1.26e-05	0.000503	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.26e-05	0.000501	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	1.25e-05	0.0005	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—NOS2—chronic obstructive pulmonary disease	1.25e-05	0.000497	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	1.24e-05	0.000492	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.23e-05	0.00049	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.22e-05	0.000488	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	1.21e-05	0.000483	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	1.19e-05	0.000472	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—ADRB2—chronic obstructive pulmonary disease	1.17e-05	0.000464	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	1.16e-05	0.000462	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	1.14e-05	0.000454	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	1.12e-05	0.000446	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.1e-05	0.000438	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	1.08e-05	0.000429	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	1.08e-05	0.000429	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	1.08e-05	0.000429	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.08e-05	0.000428	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	1.07e-05	0.000427	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	1.07e-05	0.000427	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—chronic obstructive pulmonary disease	1.07e-05	0.000425	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.06e-05	0.000423	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—ADRB2—chronic obstructive pulmonary disease	1.06e-05	0.000422	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—SERPINE1—chronic obstructive pulmonary disease	1.05e-05	0.000419	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—ALB—chronic obstructive pulmonary disease	1.05e-05	0.000418	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GC—chronic obstructive pulmonary disease	1.05e-05	0.000417	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—EDN1—chronic obstructive pulmonary disease	1.04e-05	0.000415	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.04e-05	0.000413	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—GCLC—chronic obstructive pulmonary disease	1.02e-05	0.000408	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	1.02e-05	0.000405	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—NOS3—chronic obstructive pulmonary disease	1e-05	0.0004	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—KL—chronic obstructive pulmonary disease	1e-05	0.000399	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	9.96e-06	0.000397	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—CXCL8—chronic obstructive pulmonary disease	9.96e-06	0.000397	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—GSTM1—chronic obstructive pulmonary disease	9.88e-06	0.000394	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	9.8e-06	0.000391	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	9.74e-06	0.000388	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	9.69e-06	0.000386	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	9.48e-06	0.000378	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—EDN1—chronic obstructive pulmonary disease	9.45e-06	0.000377	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—CYP1A1—chronic obstructive pulmonary disease	9.37e-06	0.000373	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—CTGF—chronic obstructive pulmonary disease	9.35e-06	0.000373	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	9.25e-06	0.000368	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—HTR2A—chronic obstructive pulmonary disease	9.11e-06	0.000363	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—KL—chronic obstructive pulmonary disease	9.01e-06	0.000359	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	8.9e-06	0.000355	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—KL—chronic obstructive pulmonary disease	8.81e-06	0.000351	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—CYP1A2—chronic obstructive pulmonary disease	8.61e-06	0.000343	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	8.33e-06	0.000332	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	8.31e-06	0.000331	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—HTR2A—chronic obstructive pulmonary disease	8.27e-06	0.00033	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	8.26e-06	0.000329	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	7.84e-06	0.000312	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	7.76e-06	0.000309	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	7.56e-06	0.000301	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	7.51e-06	0.000299	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	7.48e-06	0.000298	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	7.43e-06	0.000296	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	7.32e-06	0.000292	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—KL—chronic obstructive pulmonary disease	7.29e-06	0.00029	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	7.28e-06	0.00029	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	7.27e-06	0.00029	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—VEGFA—chronic obstructive pulmonary disease	7.23e-06	0.000288	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	7.23e-06	0.000288	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—GSTP1—chronic obstructive pulmonary disease	7.18e-06	0.000286	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—HMOX1—chronic obstructive pulmonary disease	7.09e-06	0.000282	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	6.8e-06	0.000271	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—KL—chronic obstructive pulmonary disease	6.77e-06	0.00027	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	6.75e-06	0.000269	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	6.73e-06	0.000268	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	6.72e-06	0.000268	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	6.65e-06	0.000265	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—TGFB1—chronic obstructive pulmonary disease	6.64e-06	0.000264	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	6.61e-06	0.000263	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—GSTM1—chronic obstructive pulmonary disease	6.6e-06	0.000263	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	6.5e-06	0.000259	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—ALB—chronic obstructive pulmonary disease	6.37e-06	0.000254	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	6.36e-06	0.000253	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—CYP1A1—chronic obstructive pulmonary disease	6.26e-06	0.000249	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	6.25e-06	0.000249	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—NOS3—chronic obstructive pulmonary disease	6.09e-06	0.000243	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	6.06e-06	0.000241	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—LEP—chronic obstructive pulmonary disease	6.04e-06	0.000241	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	6.01e-06	0.000239	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—LEP—chronic obstructive pulmonary disease	5.91e-06	0.000235	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GSTT1—chronic obstructive pulmonary disease	5.72e-06	0.000228	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GCLC—chronic obstructive pulmonary disease	5.66e-06	0.000225	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—CXCL8—chronic obstructive pulmonary disease	5.63e-06	0.000224	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	5.59e-06	0.000223	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	5.53e-06	0.00022	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	5.5e-06	0.000219	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Hemostasis—TP53—chronic obstructive pulmonary disease	5.46e-06	0.000218	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	5.46e-06	0.000218	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	5.27e-06	0.00021	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	5.27e-06	0.00021	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	5.26e-06	0.00021	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CTGF—chronic obstructive pulmonary disease	5.16e-06	0.000206	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—CXCL8—chronic obstructive pulmonary disease	5.11e-06	0.000204	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	5.08e-06	0.000202	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	5.03e-06	0.000201	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	4.97e-06	0.000198	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	4.89e-06	0.000195	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	4.89e-06	0.000195	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	4.86e-06	0.000194	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	4.74e-06	0.000189	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	4.64e-06	0.000185	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	4.54e-06	0.000181	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	4.53e-06	0.00018	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	4.47e-06	0.000178	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	4.43e-06	0.000176	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—ALB—chronic obstructive pulmonary disease	4.25e-06	0.00017	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	4.25e-06	0.000169	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—NOS3—chronic obstructive pulmonary disease	4.07e-06	0.000162	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	4.04e-06	0.000161	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	4.02e-06	0.00016	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	4.02e-06	0.00016	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GSTP1—chronic obstructive pulmonary disease	3.97e-06	0.000158	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.93e-06	0.000156	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—HMOX1—chronic obstructive pulmonary disease	3.91e-06	0.000156	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.84e-06	0.000153	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.82e-06	0.000152	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.73e-06	0.000149	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—EGFR—chronic obstructive pulmonary disease	3.73e-06	0.000149	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.66e-06	0.000146	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—GSTM1—chronic obstructive pulmonary disease	3.64e-06	0.000145	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.63e-06	0.000145	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.63e-06	0.000145	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	3.56e-06	0.000142	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	3.55e-06	0.000142	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	3.46e-06	0.000138	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	3.4e-06	0.000136	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	3.33e-06	0.000133	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	3.26e-06	0.00013	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.26e-06	0.00013	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.25e-06	0.000129	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	3.19e-06	0.000127	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	3.09e-06	0.000123	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	3.02e-06	0.00012	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.99e-06	0.000119	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.94e-06	0.000117	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.93e-06	0.000117	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.93e-06	0.000117	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.87e-06	0.000114	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—IL6—chronic obstructive pulmonary disease	2.87e-06	0.000114	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.74e-06	0.000109	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	2.73e-06	0.000109	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.64e-06	0.000105	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.51e-06	0.0001	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.46e-06	9.82e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	2.45e-06	9.77e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.42e-06	9.65e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—TP53—chronic obstructive pulmonary disease	2.41e-06	9.6e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.37e-06	9.46e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—ALB—chronic obstructive pulmonary disease	2.35e-06	9.36e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.26e-06	8.99e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	2.25e-06	8.97e-05	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—NOS3—chronic obstructive pulmonary disease	2.25e-06	8.95e-05	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—IL6—chronic obstructive pulmonary disease	2.21e-06	8.79e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	2.21e-06	8.79e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.99e-06	7.94e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	1.85e-06	7.38e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.82e-06	7.27e-05	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	1.7e-06	6.76e-05	CbGpPWpGaD
